Taylor Brooks

In this insightful conversation, Dr. Taylor Brooks, a clinician and researcher from the Cleveland Clinic, sheds light on bispecific antibodies like epcoritamab and glofitamab in treating aggressive B-cell lymphoma. He discusses their innovative mechanisms and how they address a critical need for patients with relapsed or refractory diffuse large B-cell lymphoma. Key findings from his study reveal promising response rates and survival outcomes, while also highlighting the necessity for further research on TP53 mutations and future treatment strategies.